DIHYDROMETHYSTICIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H16O5
Molecular Weight	276.2845
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC(=O)O[C@@H](CCC2=CC=C3OCOC3=C2)C1

InChI

InChIKey=RSIWXFIBHXYNFM-NSHDSACASA-N

InChI=1S/C15H16O5/c1-17-12-7-11(20-15(16)8-12)4-2-10-3-5-13-14(6-10)19-9-18-13/h3,5-6,8,11H,2,4,7,9H2,1H3/t11-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2401103 | https://www.ncbi.nlm.nih.gov/pubmed/26191127 | https://www.ncbi.nlm.nih.gov/pubmed/26744252 | https://www.ncbi.nlm.nih.gov/pubmed/12383029

Dihydromethysticin is one of the six major kavalactones found in the roots of kava plant. Dihydromethysticin was found to be very effective in producing analgesia in the tail immersion test. Dihydromethysticin kavalactone induces apoptosis in osteosarcoma cells through modulation of PI3K/Akt pathway, disruption of mitochondrial membrane potential and inducing cell cycle arrest. Dihydromethysticin was identified as a promising lung cancer chemopreventive agent. Low concentrations of the kavalactone (+)-dihydromethysticin enhanced the binding of ligands to the GABAA receptors on freeze-dried rat cortex preparations.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Apoptosis 155 Target ID: WP254 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26191127	Activator 1430
Cytochrome P450 3A4 127 Target ID: CHEMBL340 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12127912	Inhibitor 8297	2.5 µM [IC50]
Cytochrome P450 2C19 51 Target ID: CHEMBL3622 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12127912	Inhibitor 8297	0.43 µM [IC50]
Cytochrome P450 2C9 50 Target ID: CHEMBL3397 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12127912	Inhibitor 8297	13.35 µM [IC50]
Cytochrome P450 1A2 72 Target ID: CHEMBL3356 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12127912	Inhibitor 8297	14.8 µM [IC50]
Cytochrome P450 2D6 61 Target ID: CHEMBL289 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12127912	Inhibitor 8297	37.03 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Lung cancer 69 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26744252 https://www.ncbi.nlm.nih.gov/pubmed/27728767 https://www.ncbi.nlm.nih.gov/pubmed/28806079	Preventing	Preclinical	Unknown Approved Use Unknown
Osteosarcoma 22 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26191127	Primary	Basic research	Unknown Approved Use Unknown
Pain 614 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2401103	Primary	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Effects of kawain and dihydromethysticin on field potential changes in the hippocampus.	1997 May	9194150
Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity.	2002 Aug 16	12127912
Dihydromethysticin kavalactone induces apoptosis in osteosarcoma cells through modulation of PI3K/Akt pathway, disruption of mitochondrial membrane potential and inducing cell cycle arrest.	2015	26191127
Pilot in Vivo Structure-Activity Relationship of Dihydromethysticin in Blocking 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone-Induced O(6)-Methylguanine and Lung Tumor in A/J Mice.	2017 Sep 28	28806079

Patents

Sample Use Guides

In Vivo Use Guide

Rat: 1 mg/g of diet

Route of Administration: Oral

In Vitro Use Guide

Dihydromethysticin induced dose-dependent as well as time-dependent antiproliferative effects against MG-63 cell growth. Cell death and apoptotic body formation was noticed followed dihydromethysticin treatment at various doses. The percentage of apoptotic cells (early apoptosis+late apoptosis) increased from 6.63% in untreated control to 23.92%, 23.81% and 93.9% in 25uM, 75uM and 100uM dihydromethysticin-treated cells respectively.

Name

Type

Language

DIHYDROMETHYSTICIN

Common Name

English

NSC-112159

Code

English

(2S)-2-(2-(1,3-BENZODIOXOL-5-YL)ETHYL)-4-METHOXY-2,3-DIHYDROPYRAN-6-ONE

Systematic Name

English

Classification Tree Code System Code

DSLD

2592 (Number of products:13)